Piper Sandler Stays Overweight on Day One Biopharmaceuticals (DAWN), 'sets a new high mark among MAPK-inhibitors in this setting'
Tweet Send to a Friend
Piper Sandler analyst Erinn Murphy reiterated an Overweight rating and $35.00 price target on Day One Biopharmaceuticals (NASDAQ: DAWN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
